Breast Cancer Res Treat (2018) 168:35–41 https://doi.org/10.1007/s10549-017-4563-3 CLINICAL TRIAL Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials 1 1,2 3 3 Filipa Lynce · Matthew J. Blackburn · Ling Cai · Heping Wang · 4 5 6 1 Larry Rubinstein · Pamela Harris · Claudine Isaacs · Paula R. Pohlmann Received: 24 October 2017 / Accepted: 1 November 2017 / Published online: 8 November 2017 © Springer Science+Business Media, LLC 2017 Abstract CTEP-sponsored phase I clinical trial was 614 days for all Purpose Breast cancer (BC) is the most commonly diag- patients. Breast cancer patients were enrolled on average nosed cancer and the second leading cause of cancer-related 790 days after initial diagnosis, while non-BC patients had death among women. Given the availability of approved a median enrollment time of 582 days (p < 0.001). Breast therapies and abundance of phase II and III clinical trials, cancer patients had more clinical responses than non-BC historically few BC patients have been referred for consid- patients (18.3% vs. 4.3%, respectively). Along with the eration of participation on a phase I trial. We were inter- higher rate of response, BC patients remained on phase I ested in determining whether clinical benefit rates differed trials longer than
Breast Cancer Research and Treatment – Springer Journals
Published: Nov 8, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera